Noam Yarom: First consensus paper addressing the risk of Medication-related Osteonecrosis of the Jaw in patients with primary breast cancer

Noam Yarom, President at International Society Oral Oncology shares a post on LinkedIn:

“Our latest Clinical Practice Statement (CPS) on prevention of osteonecrosis of the jaw in primary breast cancer patients treated with adjuvant Bone Modifying Agents is now live.

This is the first consensus paper addressing the risk of Medication-related Osteonecrosis of the Jaw (MRONJ) in patients with primary breast cancer.

This patient population has unique considerations for dental treatment compared to patients with metastatic disease.

This article proposes a formula to assess the risks prior to dental treatment in order to prevent MRONJ.

This society paper builds on the foundations set by the main societies’ guideline papers, such as the MASCC/ISOO/ASCO and AAOMS, and expands the awareness and understanding of the needs of this specific patient population.

It is part of the MASCC/ISOO Clinical Practice Statement project delivered by the Oral Care Study Group, with the goal being to express the consensus of an international team of experts on selected topics related to cancer patients”

MASCC/ISOO Clinical Practice Statement: Adjuvant bone-modifying agents in primary breast cancer patients – prevention of medication-related osteonecrosis of the jaw

Authors: Noam Yarom, Catherine H Van Poznak, Joel B Epstein, Giulia Ottaviani, Yuhei Matsuda, Cesar Migliorati, and Sharon Elad 

For more information.

Source: Noam Yarom/LinkedIn